Van Eygen V - Search Results

1

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, Picchio G. Vingerhoets J, et al. Among authors: van eygen v. Antivir Ther. 2013;18(2):253-6. doi: 10.3851/IMP2358. Epub 2012 Sep 6. Antivir Ther. 2013. PMID: 22951490 Clinical Trial.

2

HIV-1 nucleotide mixture detection in the virco(®)TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing.

De Wolf H, Van Marck H, Mostmans W, Thys K, Vandenbroucke I, Van Eygen V, Pattery T, Verhasselt P, Aerssens J. De Wolf H, et al. Among authors: van eygen v, van marck h. J Virol Methods. 2011 Jul;175(1):129-32. doi: 10.1016/j.jviromet.2011.04.023. Epub 2011 Apr 27. J Virol Methods. 2011. PMID: 21549149

3

The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Kulkarni R, Babaoglu K, Lansdon EB, Rimsky L, Van Eygen V, Picchio G, Svarovskaia E, Miller MD, White KL. Kulkarni R, et al. Among authors: van eygen v. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):47-54. doi: 10.1097/QAI.0b013e31823aca74. J Acquir Immune Defic Syndr. 2012. PMID: 21997204

4

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, Boven K, Picchio G. Rimsky L, et al. Among authors: van eygen v. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):39-46. doi: 10.1097/QAI.0b013e31823df4da. J Acquir Immune Defic Syndr. 2012. PMID: 22067667 Clinical Trial.

5

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.

Rimsky L, Van Eygen V, Hoogstoel A, Stevens M, Boven K, Picchio G, Vingerhoets J. Rimsky L, et al. Among authors: van eygen v. Antivir Ther. 2013;18(8):967-77. doi: 10.3851/IMP2636. Epub 2013 May 28. Antivir Ther. 2013. PMID: 23714781 Clinical Trial.

6

Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.

Picchio GR, Rimsky LT, Van Eygen V, Haddad M, Napolitano LA, Vingerhoets J. Picchio GR, et al. Among authors: van eygen v. Antivir Ther. 2014;19(8):819-23. doi: 10.3851/IMP2771. Epub 2014 Apr 4. Antivir Ther. 2014. PMID: 24704709

7

Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE.

Van Eygen V, Thys K, Van Hove C, Rimsky LT, De Meyer S, Aerssens J, Picchio G, Vingerhoets J. Van Eygen V, et al. Among authors: van hove c. J Med Virol. 2016 May;88(5):798-806. doi: 10.1002/jmv.24395. Epub 2015 Oct 5. J Med Virol. 2016. PMID: 26412111

8

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin.

Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, Aerssens J, Witek J, Picchio G, De Meyer S, Lenz O. Fevery B, et al. Among authors: van eygen v, van rossem e. Open Forum Infect Dis. 2016 Mar 14;3(2):ofw052. doi: 10.1093/ofid/ofw052. eCollection 2016 Mar. Open Forum Infect Dis. 2016. PMID: 27186579 Free PMC article.

9

Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics.

Lombaard J, Bunupuradah T, Flynn PM, Ramapuram J, Ssali F, Crauwels H, Hoogstoel A, Van Eygen V, Stevens M. Lombaard J, et al. Among authors: van eygen v. Pediatr Infect Dis J. 2016 Nov;35(11):1215-1221. doi: 10.1097/INF.0000000000001275. Pediatr Infect Dis J. 2016. PMID: 27294305 Clinical Trial.

10

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.

Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M. Lawitz E, et al. Among authors: van eygen v, van remoortere p. J Viral Hepat. 2017 Apr;24(4):287-294. doi: 10.1111/jvh.12645. Epub 2016 Nov 23. J Viral Hepat. 2017. PMID: 27878906 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters